JP2022530524A5 - - Google Patents
Info
- Publication number
- JP2022530524A5 JP2022530524A5 JP2021564298A JP2021564298A JP2022530524A5 JP 2022530524 A5 JP2022530524 A5 JP 2022530524A5 JP 2021564298 A JP2021564298 A JP 2021564298A JP 2021564298 A JP2021564298 A JP 2021564298A JP 2022530524 A5 JP2022530524 A5 JP 2022530524A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- seq
- cancer
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024193434A JP7844591B2 (ja) | 2019-04-29 | 2024-11-05 | バイパラトピックＦＲ－α抗体及びイムノコンジュゲート |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962840297P | 2019-04-29 | 2019-04-29 | |
| US62/840,297 | 2019-04-29 | ||
| US201962879864P | 2019-07-29 | 2019-07-29 | |
| US62/879,864 | 2019-07-29 | ||
| PCT/US2020/030245 WO2020223221A1 (en) | 2019-04-29 | 2020-04-28 | Biparatopic fr-alpha antibodies and immunoconjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193434A Division JP7844591B2 (ja) | 2019-04-29 | 2024-11-05 | バイパラトピックＦＲ－α抗体及びイムノコンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022530524A JP2022530524A (ja) | 2022-06-29 |
| JP2022530524A5 true JP2022530524A5 (https=) | 2023-05-10 |
| JP7585230B2 JP7585230B2 (ja) | 2024-11-18 |
Family
ID=73028723
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564298A Active JP7585230B2 (ja) | 2019-04-29 | 2020-04-28 | バイパラトピックＦＲ－α抗体及びイムノコンジュゲート |
| JP2024193434A Active JP7844591B2 (ja) | 2019-04-29 | 2024-11-05 | バイパラトピックＦＲ－α抗体及びイムノコンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193434A Active JP7844591B2 (ja) | 2019-04-29 | 2024-11-05 | バイパラトピックＦＲ－α抗体及びイムノコンジュゲート |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US11396543B2 (https=) |
| EP (1) | EP3962935A4 (https=) |
| JP (2) | JP7585230B2 (https=) |
| KR (1) | KR20220004687A (https=) |
| CN (1) | CN114222756A (https=) |
| AU (1) | AU2020265568B2 (https=) |
| CA (1) | CA3138272A1 (https=) |
| IL (1) | IL287451A (https=) |
| MA (1) | MA55818A (https=) |
| SG (1) | SG11202111109UA (https=) |
| TW (2) | TWI872065B (https=) |
| WO (1) | WO2020223221A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201509043RA (en) * | 2013-05-14 | 2015-12-30 | Immunogen Inc | Anti-folr1 immunoconjugate dosing regimens |
| CN113150145B (zh) | 2013-08-30 | 2025-02-14 | 伊缪诺金公司 | 用于检测叶酸受体1的抗体和测定 |
| MA55818A (fr) * | 2019-04-29 | 2022-03-16 | Immunogen Inc | Anticorps et immunoconjugués de fr-alpha biparatopique |
| CA3173944A1 (en) * | 2021-01-13 | 2022-07-21 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
| US20240209080A1 (en) * | 2021-04-10 | 2024-06-27 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
| EP4347661A4 (en) * | 2021-06-04 | 2025-06-18 | ImmunoGen, Inc. | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA |
| EP4489859A1 (en) | 2022-03-09 | 2025-01-15 | Astrazeneca AB | Binding molecules against fr alpha |
| TW202409080A (zh) * | 2022-07-26 | 2024-03-01 | 美商沙塔克實驗室股份有限公司 | 用於治療卵巢癌之組合療法 |
| CN120936382A (zh) | 2023-02-16 | 2025-11-11 | 阿斯利康(瑞典)有限公司 | 采用治疗性结合分子治疗癌症的组合疗法 |
| WO2025094146A1 (en) | 2023-11-02 | 2025-05-08 | Immunogen Switzerland Gmbh | Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates |
| US12600795B2 (en) | 2023-12-26 | 2026-04-14 | Medicovestor, Inc. | Oligomeric IgG for immunotherapeutics and diagnostics |
| WO2025252094A1 (zh) * | 2024-06-05 | 2025-12-11 | 长春金赛药业有限责任公司 | 靶向叶酸受体α(FRα)的抗体、双特异性抗体和偶联物，及其制备和用途 |
| US20260001950A1 (en) * | 2024-07-01 | 2026-01-01 | Medicovestor, Inc. | Methods of enhancing efficacy of immunoconjugates using paired human antibodies targeted at non-overlapping b-cell epitopes on the same antigen |
| US20260078179A1 (en) * | 2024-07-18 | 2026-03-19 | Novarock Biotherapeutics, Ltd. | Cdh17 antibodies and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3101034A1 (en) | 2004-02-12 | 2016-12-07 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| CA2607444C (en) | 2005-04-22 | 2015-03-10 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| EP1900752A1 (en) | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
| TWI622402B (zh) | 2010-02-24 | 2018-05-01 | 免疫遺傳股份有限公司 | 葉酸受體１抗體類和免疫共軛物類及彼等之用途 |
| MX343607B (es) | 2010-11-05 | 2016-11-11 | Morphotek Inc | Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato. |
| BR112013025415B1 (pt) | 2011-04-01 | 2021-03-16 | Immunogen, Inc | uso de um imunoconjugado antirreceptor de folato 1 (folr1) |
| WO2012138749A1 (en) | 2011-04-04 | 2012-10-11 | Immunogen, Inc. | Methods for decreasing ocular toxicity of antibody drug conjugates |
| US9200073B2 (en) | 2012-08-31 | 2015-12-01 | Immunogen, Inc. | Diagnostic assays and kits for detection of folate receptor 1 |
| SG11201509043RA (en) | 2013-05-14 | 2015-12-30 | Immunogen Inc | Anti-folr1 immunoconjugate dosing regimens |
| CN113150145B (zh) | 2013-08-30 | 2025-02-14 | 伊缪诺金公司 | 用于检测叶酸受体1的抗体和测定 |
| PL3055332T3 (pl) | 2013-10-08 | 2020-02-28 | Immunogen, Inc. | Schematy dawkowania immunokoniugatu anty-FOLR1 |
| WO2015186823A1 (ja) | 2014-06-06 | 2015-12-10 | 協和発酵キリン株式会社 | Ｆｏｌｒ１標的薬および葉酸代謝拮抗剤によるがん患者のための治療方法並びに医薬 |
| SG11201701328XA (en) | 2014-09-02 | 2017-03-30 | Immunogen Inc | Methods for formulating antibody drug conjugate compositions |
| CN116440279B (zh) * | 2015-09-17 | 2026-02-24 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
| TWI781145B (zh) * | 2017-02-28 | 2022-10-21 | 美商伊繆諾金公司 | 具有自分解肽連接子之類美登素衍生物及其結合物 |
| GB201707864D0 (en) | 2017-05-16 | 2017-06-28 | Inst Of Cancer Research: Royal Cancer Hospital | Platinum-reistant cancer treatment |
| US20200284810A1 (en) | 2017-09-05 | 2020-09-10 | Immunogen, Inc. | Methods for detection of folate receptor 1 in a patient sample |
| EP3684409A4 (en) | 2017-09-22 | 2021-06-23 | Immunogen, Inc. | SEPARATION OF TRIPLE LIGHT CHAIN ANTIBODIES USING CATION EXCHANGE CHROMATOGRAPHY |
| US11274121B2 (en) | 2018-01-12 | 2022-03-15 | Immunogen, Inc. | Methods for antibody drug conjugation, purification, and formulation |
| MA55818A (fr) * | 2019-04-29 | 2022-03-16 | Immunogen Inc | Anticorps et immunoconjugués de fr-alpha biparatopique |
| EP4347661A4 (en) * | 2021-06-04 | 2025-06-18 | ImmunoGen, Inc. | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA |
-
2020
- 2020-04-28 MA MA055818A patent/MA55818A/fr unknown
- 2020-04-28 TW TW109114175A patent/TWI872065B/zh active
- 2020-04-28 KR KR1020217037919A patent/KR20220004687A/ko active Pending
- 2020-04-28 AU AU2020265568A patent/AU2020265568B2/en active Active
- 2020-04-28 TW TW113151397A patent/TW202515623A/zh unknown
- 2020-04-28 US US16/860,822 patent/US11396543B2/en active Active
- 2020-04-28 CA CA3138272A patent/CA3138272A1/en active Pending
- 2020-04-28 CN CN202080037442.7A patent/CN114222756A/zh active Pending
- 2020-04-28 WO PCT/US2020/030245 patent/WO2020223221A1/en not_active Ceased
- 2020-04-28 SG SG11202111109UA patent/SG11202111109UA/en unknown
- 2020-04-28 EP EP20798751.2A patent/EP3962935A4/en active Pending
- 2020-04-28 JP JP2021564298A patent/JP7585230B2/ja active Active
-
2021
- 2021-10-20 IL IL287451A patent/IL287451A/en unknown
-
2022
- 2022-06-10 US US17/838,016 patent/US11834498B2/en active Active
-
2023
- 2023-10-24 US US18/493,623 patent/US20240182560A1/en not_active Abandoned
-
2024
- 2024-11-05 JP JP2024193434A patent/JP7844591B2/ja active Active
-
2025
- 2025-08-12 US US19/297,369 patent/US20260061058A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022530524A5 (https=) | ||
| US20240173427A1 (en) | Glypican 3 antibodies and conjugates thereof | |
| US20230138930A1 (en) | Tissue factor-targeted antibody-drug conjugate | |
| ES2895623T3 (es) | Conjugación de sitio específico de fármacos enlazadores con anticuerpos y ADC resultantes | |
| US20230173093A1 (en) | Charge variant linkers | |
| CN105451775B (zh) | 药物抗体缀合物 | |
| US10618935B2 (en) | Antibody-drug conjugate (ADC) and method for forming the same | |
| CN110240654A (zh) | 结合cd73的抗体-药物偶联物 | |
| RU2019129839A (ru) | Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты | |
| US12006370B2 (en) | Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy | |
| US20210260212A1 (en) | Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapy | |
| CN107614488A (zh) | 新型亲水连接体和其在配体‑药物共轭偶联物上的应用 | |
| JP2021528471A5 (https=) | ||
| JP2023504187A5 (https=) | ||
| CN113121639B (zh) | 澳瑞他汀类似物及其偶联物、其制备方法及其应用 | |
| CN120835792A (zh) | 抗体-药物偶联物靶向治疗前列腺癌和其他肿瘤 | |
| IL273384B2 (en) | Methods of preventing methionine oxidation in immunoconjugates | |
| US20250049938A1 (en) | Antibody-drug conjugate and use thereof | |
| CN115052663A (zh) | Alk5抑制剂缀合物及其用途 | |
| CN119156231A (zh) | 提高鹅膏蕈毒素-抗体缀合物的治疗指数的方法 | |
| JP2025539807A5 (https=) | ||
| RU2021130453A (ru) | Бипаратопные fr-альфа антитела и иммуноконъюгаты | |
| RU2023100251A (ru) | Антитело против клаудина 18.2 и его конъюгат антитело-лекарственное средство | |
| RU2021104563A (ru) | Конъюгаты антитело-лекарственное средство и их применение |